2010至2022年儿童局灶性脑动脉病的管理变化
比较VIPS I(2010-2014)与VIPS II(2016-2022)两项前瞻性队列中局灶性脑动脉病(FCA)患儿的特征与治疗。VIPS II中静脉皮质激素治疗比例从5%升至56%,基线病情更重(FCA严重度评分中位数6 vs 4,P=0.006),但疾病进展和12个月神经结局无显著差异。
要点
- VIPS II中FCA患儿静脉皮质激素使用率从VIPS I的5%增至56%。
- VIPS II的FCA患儿基线病情更重,FCA严重度评分中位数6 vs 4(P=0.006)。
- 两队列间FCA严重度评分变化及12个月神经结局无显著差异。
核心结论
- VIPS I与VIPS II研究间FCA的皮质激素治疗大幅增加,VIPS II病例基线更重,但疾病进展或神经结局无显著差异。
- 鉴于支持皮质激素治疗证据水平低,儿童卒中中心应让FCA患者参加正在进行的FCA皮质激素治疗试验。
研究设计与样本
- VIPS II前瞻性队列研究,2016年12月至2022年1月在22个中心纳入205例动脉缺血性卒中儿童(29天至18岁)。
- 由神经影像学家和儿童血管神经病学家独立复核影像和临床数据以分类卒中原因,并与已发表的VIPS I(2010-2014,37个中心)FCA队列比较。
主要发现
- VIPS II中75例明确动脉病患者中32例(43%)为FCA,VIPS I中127例明确动脉病中41例(32%)为FCA。
- VIPS I的FCA患者中位年龄11.3岁(56%男性),VIPS II中位年龄11.4岁(55%男性)。
- 静脉皮质激素治疗从VIPS I的2/41(5%)增至VIPS II的18/32(56%)。
- VIPS II的FCA病例基线更重(FCA严重度评分中位数6 vs 4;P=0.006)。
- FCA严重度评分从基线至最大值的变化及12个月神经结局均无显著差异。
临床怎么用
- 鉴于支持皮质激素治疗证据水平低,儿童卒中中心应让FCA患者参加正在进行的FCA皮质激素治疗试验。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most common cause of arterial ischemic stroke in healthy children, focal cerebral arteriopathy (FCA), can progress rapidly over days with worsening brain injury. A 2017 retrospective Swiss study of corticosteroid treatment for FCA changed practice. To assess its impact, we compared the FCA cohorts from the 2 VIPS (Vascular Effects of Infection in Pediatric Stroke) prospective cohort studies. METHODS: The VIPS II study prospectively enrolled 205 children (29 days to 18 years) with arterial ischemic stroke at 22 centers, December 2016 to January 2022. The local team measured 12-month outcomes using the pediatric stroke outcome measure. A neuroradiologist and pediatric vascular neurologist independently reviewed all clinically obtained imaging and clinical data to classify the cause of arterial ischemic stroke. The neuroradiologist measured the FCA Severity Score on vascular imaging performed at any time poststroke. We compared the VIPS II FCA cohort to the previously published FCA cohort from VIPS I (2010-2014; 37 centers). RESULTS: Of 75 children with definite arteriopathy enrolled in VIPS II, 32 (43%) had FCA, compared with 41 of 127 (32%) of definite arteriopathy cases in VIPS I. The median age was 11.3 years (56% male) in VIPS I and 11.4 years (55%) in VIPS II. Treatment with intravenous corticosteroids increased from 2 of 41 (5%) of FCA patients in VIPS I to 18 of 32 (56%) in VIPS II. The VIPS II FCA cases were more severe at baseline (median FCA Severity Score 6 versus 4; P=0.006). There were no significant differences in either the change in FCA Severity Score (baseline to maximum) or the 12-month neurological outcomes. CONCLUSIONS: Treatment of FCA with corticosteroids increased dramatically between the VIPS I and VIPS II studies. VIPS II cases were more severe at baseline, but we observed no significant difference in disease progression or neurological outcomes. Given the low level of evidence supporting corticosteroid therapy, pediatric stroke centers should enroll FCA patients into ongoing FCA corticosteroid treatment trials. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT04873583 and NCT06040255.
引用
- Fullerton HJ, Hills NK, Chen H, et al. Changing Management of Focal Cerebral Arteriopathy of Childhood From 2010 to 2022. Stroke. 2025. PMID: 40351190. doi:10.1161/STROKEAHA.124.050550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。